The popularity of Viagra initially drove a boom for major pharmaceutical companies, however recent shifts present a complicated outlook for shareholders. Lower-cost alternatives are eating into earnings, and continued legal battles add further complexity to the landscape. While specific companies might still gain from related products, the general